Skip to main content
Clinical Trials/NCT06724471
NCT06724471
Active, not recruiting
Not Applicable

Preservation of Women's Fertility: Evaluation of Innovative Methods for Ovarian Tissue Cryopreservation

University Hospital, Clermont-Ferrand1 site in 1 country30 target enrollmentMay 5, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Infertility, Female
Sponsor
University Hospital, Clermont-Ferrand
Enrollment
30
Locations
1
Primary Endpoint
Post-thawing Ovarian Follicle morphology
Status
Active, not recruiting
Last Updated
10 months ago

Overview

Brief Summary

The recent innovations in cancer diagnosis and therapy have improved the five-year survival for patients. However, anticancer treatments may impair patient fertility; therefore fertility preservation is recommended before therapy initiation. The sole method for preserving young prepubescent girls' fertility, which can also be used for pubescent women, is ovarian tissue cryopreservation (OTC) with later auto-transplantation. Although 200 births have been reported worldwide after OTC and transplantation, significant improvements are required. Indeed, freezing and thawing protocols vary according to laboratories (media, cryoprotectants, freezing curve, etc...) and selection criteria are not justified. In addition, most of the laboratories use unsafe devices (e.g. screw cap cryovials) for OTC, exposing ovarian tissues to biological hazards during sample storage in nitrogen tanks. To eliminate these risks, novel "high security" devices have been commercialized (welded cryotubes). However, while thermal welding could alter tissue quality, the functionality of the human ovarian tissue frozen with these innovative devices has not yet been evaluated. The objectives of this study are i) to optimize the freezing and the thawing protocols for human OTC according to thermodynamic properties of the freezing medium and the type of device (welded or screwed cryotube) and ii) to determine if the type of cryotube influences the quality of human ovarian tissue.

This project will enable to reach a better understanding of the impact of freezing on ovarian tissue functionality, as well as the implementation of an optimal protocol for OTC within the ART laboratory of Clermont-Ferrand hospital to optimize patient care.

Detailed Description

The aim of this project is to determine whether the type of cryogenic tube (with screw caps or thermosoldered) influences the quality and functionality of ovarian tissue after cryopreservation. First, a characterization of the thermodynamic properties of the freezing medium using a differential scanning calorimeter (Diamond DSC, PerkinElmer) will be carried out to optimize freezing and thawing protocols. This analysis will define important parameters such as crystallization temperature (Tc), end-of-melting temperature (Tm), and transition temperatures (Tg'1). Once freezing and thawing protocols are optimized, the investigators will use human ovarian cortex surrounding benign cysts, a model previously validated by our laboratory, to determine whether the type of cryotube influences the quality of human ovarian tissue. These ovarian cortical samples usually destroyed in clinics share similar characteristics with normal ovarian cortex. Ovarian tissue will be cut into 1mm3 fragments and divided into three groups: fresh ovarian cortex (group1, control), ovarian cortex cryopreserved in thermosoldered cryogenic tubes (group 2) or in screw cap (group 3). The investigators will assess ovarian tissue quality immediately after resection for group 1 or after thawing for group 2 and 3 by analyzing follicle density and morphology (HES staining) and proliferation/apoptosis balance (Immunohistochemistry (IHC) for KI67 and cleaved caspase 3). To assess the functionality of the ovarian tissue after thawing, ovarian cortex fragments will be in vitro cultured. The investigators will analyze i) follicle density, type and morphology (HES staining), ii) the proliferation/apoptosis balance (IHC for KI67 and cleaved caspase 3), iii) the expression levels of major folliculogenesis regulators (IHC for GDF-9) and iv) the levels of folliculogenesis-associated hormones (AMH, estrogen) secreted in culture medium.

Registry
clinicaltrials.gov
Start Date
May 5, 2022
End Date
December 31, 2025
Last Updated
10 months ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
University Hospital, Clermont-Ferrand
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult woman scheduled for benign ovarian cyst resection (dermoid, functional, mucinous or serous cysts)
  • Below 37 years old and above 18 years old
  • Capable of giving written informed consent to participate in the research study
  • Affiliated to social welfare service

Exclusion Criteria

  • Women above 37 years old and below 18 years old
  • Polycystic ovary syndrome
  • Diminished ovarian reserve
  • Severe endometriosis
  • Malignant and endometrial cysts

Outcomes

Primary Outcomes

Post-thawing Ovarian Follicle morphology

Time Frame: 24 months

Follicle morphology of fresh versus frozen (with thermosoldered or screwed cryovials)/thawed ovarian cortex will be assessed on serial sections stained with hematoxylin-eosin-saffron. Fragments will be fixed on the day of collection for group 1 and directly after thawing for groups 2 and 3. Morphology of follicles will be evaluated according to the parameters described by Keros et al. Hum Reprod. 2009.

Secondary Outcomes

  • Post-thawing Ovarian Follicle density(24 months)
  • Post-thawing Ovarian Follicle proliferation(24 months)
  • Post-thawing Ovarian Follicle apoptosis(24 months)
  • Ovarian Follicle stage after organotypic culture(36 months)
  • Ovarian Follicle morphology after organotypic culture(36 months)
  • GDF-9 expression after organotypic culture(36 months)
  • Proliferation after organotypic culture(36 months)
  • Apoptosis after organotypic culture(36 months)
  • AMH secretion after organotypic culture(36 months)
  • Estrogen secretion after organotypic culture(36 months)
  • Thermodynamic properties of freezing medium(12 months)

Study Sites (1)

Loading locations...

Similar Trials